# US 8,278,342 B2 · Therapeutic compounds for blocking DNA synthesis of pox viruses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,342 B2
- Document ID: US8278342B2
- Status: Granted
- Kind: B2
- Application number: 12/537,083
- Filed: 2009-08-06
- Published: 2010-02-11
- Granted: 2012-10-02
- Earliest claimed: 2009-08-06
- Assignees: The Trustees of the University of Pennsylvania
- Inventors: Robert P. Ricciardi
- Web page: https://patentgrep.com/patent/US8278342B2

## CPC

- A61K 31/65: Tetracyclines
- A61K 31/095: Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K 31/10: Sulfides; Sulfoxides; Sulfones
- A61K 31/166: having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/341: not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A61K 31/351: not condensed with another ring
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 31/357: having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K 31/42: Oxazoles
- A61K 31/426: 1,3-Thiazoles
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/429: condensed with heterocyclic ring systems
- A61K 31/473: ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61P 31/20: for DNA viruses
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention provides methods of inhibiting replication of a poxvirus by contacting a poxvirus with a compound having formula XVII which in turn reduce, inhibit, or abrogate poxvirus DNA polymerase activity and/or its interaction with its processivity factor. Formula XVII can be utilized to treat humans and animals suffering from a poxvirus infection. Pharmaceutical compositions for treating poxvirus infected subjects are also provided.

## Claims

### Claim 1

A method of inhibiting, treating, or abrogating a poxvirus infection in a subject comprising the step of administering to said subject a compound having the formula XVII:
whereby said compound reduces, inhibits, or abrogates activity of a DNA polymerase of said poxvirus, thereby inhibiting, treating, or abrogating a poxvirus infection in the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein said step of inhibiting replication of a poxvirus comprises inhibiting DNA synthesis.

### Claim 3 (depends on 1)

The method of claim 1, wherein said poxvirus is a vaccinia virus or a variola virus.

### Claim 4 (depends on 1)

The method of claim 1, wherein said DNA polymerase is an E9 DNA polymerase or a homologue thereof from a different species.

### Claim 5 (depends on 1)

The method of claim 1, whereby said compound reduces, inhibits, or abrogates interaction of said DNA polymerase with a processivity factor, thereby affecting activity of said DNA polymerase.

### Claim 6 (depends on 5)

The method of claim 5, wherein said processivity factor is an A20 or D4R processivity factor or a homologue thereof from a different species.
